The efficacy of the suicide gene therapy using the herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) system for the treatment of cancer is limited because of the insufficient gene transfer and the low killing activity. To enhance the antitumor activity, we determined whether recombinant adenovirus vector (rAd)s expressing both HSV-tk and monocyte chemoattractant protein-1 (MCP-1) genes could potentiate the destruction of hepatocellular carcinoma (HCC). The rAd Ad-tk-MCP1 harboring HSVtk and MCP-1 genes in sequence under the universal CAG promoter was constructed with a bicistronic unit including the encephalomyocarditis virus-internal ribosomal entry site. The levels of HSV-tk expression and GCV-sensitive tumoricidal activity of Ad-tk-MCP1 were comparable to those of rAd expressing HSV-tk alone. The growth of subcutaneous tumors in athymic nude mice was markedly suppressed when tumors were treated with Ad-tk-MCP1 as opposed to another bicistronic vector Ad-MCP1-tk, rAd expressing either HSV-tk or MCP-1, or both of these vectors. The antitumor effects of Ad-tkMCP1 may be dependent on the activation of macrophages, since the recruitment of macrophages was observed tumor necrosis factor-a production was enhanced in the tumor tissue. Furthermore, the enhanced antitumor effect was abolished by inactivating macrophages with carrageenan treatment. These results demonstrated that a bicistronic rAd harboring both suicide and chemokine genes in sequence exerted the enhanced, macrophage-dependent, antitumor effects in a model of HCC and support the use of this strategy for the treatment of HCC.
H epatocellular carcinoma (HCC) is one of the most common human malignancies worldwide. While a minority of the patients are cured by conventional treatments, [1] [2] [3] [4] the prognosis is poor for most patients because tumor cells inevitably survive in spite of chemotherapy and grow to form locally recurrent and distant metastatic lesions. Newly established treatments, such as gene therapy, have the potential to more effectively induce tumor cell death compared to conventional treatments.
Gene therapy strategies for cancer can be divided into three major categories: enzyme/prodrug systems also called suicide gene therapy; [5] [6] [7] immune-gene therapy: 8, 9 and tumor suppressor gene replacement therapy. [10] [11] [12] We recently proposed a strategy for the combining suicide gene therapy and chemokine gene delivery for the treatment of HCC, which was based on data suggesting that adenovirally delivered monocyte chemoattractant protein-1 (MCP-1) enhanced the antitumor effects of herpes simplex virus thymidine kinase/ganciclovir (HSV-tk/GCV) by recruitment and activation of macrophages. 13 HSV-tk induces tumor cell death in the presence of the prodrug, GCV, [5] [6] [7] not only in the infected cells, but also in neighboring uninfected tumor cells via a bystander effect.
14-16 MCP-1 regulates the recruitment of macrophages into inflammatory sites and tumor tissues, as well as their activation, 17 thereby facilitating the macrophagemediated phagocytosis of apoptotic cells.
When the coexpression of two different genes in the tumor tissues is achieved by using two different promoters of the distinct vectors, their expression may be uncoupled by interfering with the activity of their promoters and the vectors at the single-cell level, or by the insufficient simultaneous transduction of the two vectors in the cell. [18] [19] [20] Supporting this notion are our data showing an insufficient HCC tumor killing response when gene therapy was carried out using two recombinant adenovirus vector (rAd)s. 18 In the current study, we set out to determine if rAds expressing both the HSV-tk and MCP-1 genes under the transcriptional control of a single promoter within a bicistronic unit can potentiate their antitumor effectiveness. We demonstrated that treatment with the bicistronic rAd followed by GCV administration resulted in a strong antitumor response compared to that obtained using rAd expressing either HSV-tk or MCP-1, or with the mixture of both rAds. The mechanism underlying this antitumor effect was examined in part by evaluating the activation status of the macrophages.
Materials and methods

Recombinant adenoviruses
Bicistronic recombinant replication-defective adenovirus vector Ad-tk-MCP1 and Ad-MCP1-tk (Fig 1) harboring the human MCP-1 gene and HSV-tk genes, respectively, driven by the CAG promoter were prepared, purified and titrated according to the protocols supplied by the manufacturer (Takara, Shiga, Japan). Briefly, the internal ribosomal entry site (IRES) fragment of encephalomyocarditis virus (EMCV) with XhoI-EagI restriction enzyme sites was inserted into the plasmid pSP73 (Promega, San Luis Obispo, CA) containing the human MCP-1 gene, generating pSP73-IRES-MCP1. The tk fragment containing the HSV-tk gene with the XhoI-XbaI restriction enzyme site was inserted into the pSP73-IRES-MCP1, generating the pSP73-tk-IRES-MCP1 (ptk-MCP1). The IRES fragment of EMCV with the XhoI-PvuII restriction enzyme site was inserted into the pSP73 containing HSVtk gene, generating pSP73-IRES-tk. The MCP1 fragment with the XhoI-XbaI restriction enzyme site was inserted into the pSP73-IRES-tk, generating the pSP73-MCP1-IRES-tk (pMCP1-tk). The two plasmids were digested by HpaI and SspaI restriction enzymes, and the resultant fragments were blunted using a Takara blunting kit and were inserted into the SwaI site of the pAxCAwt cosmid (Takara) under the control of CAG promoter, containing nearly the full length of the adenovirus type 5 genome lacking the E1 and E3 regions, to generate pAd.CAG-tk-MCP1 and pAd.CAG-MCP1-tk. Subsequently, the Ad-tk-MCP1 and Ad-MCP1-tk were generated by transfecting 293 cells with pAd.CAG-tk-MCP1 and pAd.CAG-MCP1-tk and EcoT22I digested adenovirus 5-dIX DNA-terminal protein complex (Fig 1) . 21 The Ad-MCP1, Ad-tk and Ad-lacZ were constructed as previously described and propagated in 293 cells. 22 The rAds were purified on a cesium gradient and the titer of rAd was determined by the 50% tissue culture infectious dose (TCID 50 ) method. 23 
Cell line and culture
The human HCC cell line HuH7 24 was used in in vitro and in vivo experiments. Cells were cultured in Dulbecco's modified Eagle medium (DMEM) (Gibco, Long Island, NY) supplemented with 10% heat-inactivated fetal bovine serum (Gibco).
Enzme-linked immunosorbent assay (ELISA) for MCP-1
Aliquots of 1 Â 10 5 HuH7 cells were seeded in 1.0 ml of culture media in a 12-well tissue culture plate. After 24 hours, the cells were infected with Ad-MCP1-tk, Ad-tk-MCP1, Ad-MCP1 and Ad-MCP1, together with Ad-tk, at various multiplicity of infection (MOI)s. After 48 hours, the media were collected from the wells. The concentration of MCP-1 in the collected media from each well was determined by ELISA as described previously. 25 Briefly, each well of 96-well microtiter plate was coated with monoclonal anti-human MCP-1 antibody (ME61;1 mg/ml) overnight at 41C. After washing, the plates were blocked by incubation with phosphatebuffered saline (PBS) containing 1% bovine serum albumin for 1 hour at 371C. The diluted sample media were added and the plate was then incubated for 2 hours at 371C. Following incubation, the plates were washed and incubated with rabbit anti-MCP-1 antibody (1 mg/ ml), followed by alkaline phosphatase-conjugated goat anti-rabbit antibody (1/12,000, Tago, Burlingame, CA), each for 2 hours at 371C. After the plate was washed, aliquots of 1 mg/ml p-nitrophenylphosphate (Sigma, St Louis, MO) in 1 M diethanolamine (Sigma) (pH 9.8) supplemented with 0.5 mM MgCl 2 were added to the wells and the plate was incubated for 40 minutes at room temperature. After the addition of 1 M NaOH, the optical density (405 nm wavelength-OD 405 ) was assessed using an ELISA plate reader (MTP-120; Corona Electric, Ibaragi, Japan).
Enzymatic assay for HSV-tk
Aliquots of 1 Â 10 6 cells were seeded in 5 ml of culture media in a six-well tissue culture plate. The cells were infected with Ad-MCP1-tk, Ad-tk-MCP1, Ad-tk and Ad-MCP1 plus Ad-tk were infected at various MOIs 24 hours later and the media and cells were then collected from the wells after 72 hours. To measure HSV-tk activity, an enzymatic assay of HSV-tk was utilized as reported previously. 7 Briefly, after washing twice with 2 ml of lysis buffer containing 10 mM Tris-HCI (pH 7.5), 1 mM DTT, 1 mM EDTA and 20% glycerol, a cell lysate debris was obtained by centrifugation. The cell pellet was then suspended in 0.1 ml of lysis buffer containing 200 mg/ml of Pefabloc SC (Boehringer Mannheim, Indianapolis, IN), 40 mg/ml of aprotinin (Boehringer Mannheim) and 5 mg/ml of leupeptin (Boehringer Mannheim). A cell lysate was obtained by centrifugation of the cells destructed with sonication. Protein was quantified using the Bradford method. 26 For each sample containing 50 mg protein, [ 3 H] GCV (Moravek Biochemicals Inc., Brea, CA) was counted using a scintillation counter according to previously reported procedure with a slight modification. 27 All experiments were carried out in duplicated, and the data were expressed as the mean cpm/mg.
In vitro GCV sensitivity
The sensitivity of the infected cells to GCV was determined using a nonradiactive cell proliferation assay according to the manufacture's protocol (Cell Proliferation Reagent WST-1, Roche Molecular Biochemicals). At 24 hours after 5 Â 10 3 cells were plated in triplicate wells in a 96-well plate, cells were infected with each rAd at different MOIs. At 48 hours after infection, increasing concentrations (0, 1, 10 and 100 mg/ml) of GCV (Tanabe Pharmaceutical Drug, Tokyo, Japan) were added to the wells. After 4 days, the percentage of surviving cells was calculated as a percentage of absorbance found in the GCV-treated cells divided by that found in the cells without GCV treatment (mean7SD).
Animal experiments
Male athymic nude mice (7-weeks old) (BALB/cA Jcl-nu; CLEA Japan) were subcutaneously injected with 1 Â 10 7 HuH7 cells on day 0. On days 3 and 4, 1 Â 10 7 TCID 50 (100 ml) of Ad-MCP1-tk, Ad-tk-MCP1, Ad-tk, Ad-MCP1, Ad-MCP1 plus Ad-tk (5 Â 10 6 TCID 50 , of each), Ad-lacZ or PBS (100 ml) was injected into the tumor. A measure of 75 mg/kg of GCV was then administered into the peritoneal cavity daily for the next five consecutive days (days 5-9). In some experiments, 1 ml of 2 mg/ml carrageenan (Sigma), a compound known to inactivate macrophage in vivo, 28 was administered into the peritoneal cavity of the mice on days 3, 4, 5, 12, 19 and 26. Tumor size was measured every 3 day and tumor volume was calculated using the following equation: (the longest diameter) Â (the shortest diameter) 2 /2. For histopathological analysis, tumor tissues were fixed in 10% zincbuffered formalin, embedded in paraffin, sectioned with 2 mm thickness and stained with hematoxylin and eosin. Animal experiments were conducted in accordance with institutional guidelines.
Immunohistochemical analysis
Tumor tissues resected on day 10 were embedded in OCT compound (Sakura Finetek, Torrance, CA) and snapfrozen in liquid nitrogen. Cryostat sections of frozen tissues were fixed in cold acetone for 10 minutes, followed by three rinses in PBST. To avoid nonspecific staining, avidin and biotin in the tissues were blocked using a blocking kit (Vector Laboratories, Inc., Burlingame, CA). The slides were then incubated with biotin-conjugated anti-Mac-1 (CD11b) antibody (1:100) (M1/7; Pharmingen) for 30 minutes at room temperature. Biotin-conjugated rat IgG 2b k was used as the negative control. The reaction was visualized using a VECTASTIN ABC Standard Kit (Vector Laboratories), followed by counterstaining with hematoxylin. Serial sections were fixed in 10% zinc-buffered formalin and stained with hematoxylion and eosin.
Reverse transcriptional polymerase chain reaction (RT-PCR) for tumor necrosis factor (TNF) a gene expression Total RNA was extracted from tumor tissues resected on day 10 using a Total Cellular RNA Isolation Kit (Ambion, Inc.) according to the manufacturer's protocol. RT-PCR was performed with 1 mg of total RNA and an Oligo dT-Adaptor Primer, by using an RNA PCR Kit (AMV) Ver.2.1 (Takara). PCR was run for 2 minutes at 941C followed by 25 or 30 cycles of 30 seconds at 941C, 30 seconds at 601C AND 1.5 minutes at 721C. The PCR primers for mouse TNF-a and GAPDH genes were purchased from R&D System, Inc.
Statistical analysis
Results were expressed as means7SE. Differences between groups were analyzed for statistical significance using Mann-Whitney U-test because of the small sample size and lack of a valid assumption for a normal distribution. P-values of o.05 were considered statistically significant.
Results
MCP-1 production of recombinant adenoviruses in vitro
Production of MCP-1 in HuH7 cells infected with Ad-MCP1-tk, Ad-tk-MCP1, Ad-MCP1 and Ad-MCP1 plus Ad-tk was measured by ELISA every 24 hours after infection. MCP-1 production reached a peak level 48 hours after infection with rAds (data not shown), which was consistent with our previous observations. 13 MCP-1 production was compared at varying MOIs (Fig 2) . MCP-1 produced by Ad-MCP1 reached a peak level at an MOI of 33.3 and remained elevated at higher MOIs. Similarly, the amounts of MCP-1 produced by Ad-MCP1-tk and Ad-tk-MCP1 were increased as the MOIs were increased and reached a peak level at an MOI of 100, although the levels were 1/3 and 1/50 of those seen with Ad-MCP1, respectively. The cells coinfected with Ad-tk and Ad-MCP1 produced a large amount of MCP-1 comparable to that obtained by a single infection with Ad-MCP1. These data indicated that MCP-1 produced by bicistronic rAd under the control of CAG promoter was less than that produced by Ad-MCP1 alone.
HSV-tk production and tumoricidal activity of recombinant adenoviruses in vitro
Production of HSV-tk in HuH7 cells infected with Ad-MCP1-tk, Ad-tk-MCP1, Ad-tk and Ad-MCP1 plus Ad-tk was quantified every 24 hours after infection. HSVtk production reached a peak level 72 hours after infection with Ad-tk-MCP1, Ad-tk and Ad-MCP1 plus Ad-tk and 120 hours after infection with Ad-MCP1-tk (data not shown). Production was compared at varying MOIs (Fig 3) . The amounts of HSV-tk produced by Ad-tk, Ad-tk-MCP1 and Ad-MCP1 plus Ad-tk reached a peak level at an MOI of 33.3 and remained elevated when higher MOIs were used. In contrast, HSV-tk produced by Ad-MCP1-tk was profoundly decreased, when compared to the other adenovirus systems.
Survival rates of infected HuH7 cells were monitored by WST-1 assay to determine the tumoricidal activity of the recombinant adenoviruses (Fig 4) . The Ad-tk-MCP1, Ad-tk, Ad-MCP1 plus Ad-tk and Ad-tk plus Ad-lacZ caused a marked decrease in cell survival, with less than 40% of cells surviving in the presence of 1 mg/ml of GCV and almost no cells surviving in the presence of 100 mg/ml of GCV (Fig 4a) . In contrast, the Ad-MCP1-tk greatly attenuated the tumoricidal activity. The Ad-lacZ had no effect at any of the GCV concentrations. Survival rates of infected HuH7 cells were also monitored by the WST-1 assay to assess the tumoricidal activity at varying MOIs in the presence of 10 mg/ml of GCV (Fig 4b) . Ad-tk-MCP1, Ad-tk and Ad-MCP1 plus Ad-tk resulted in the ) cells were seeded in a well of 12-well plates with 1.0 ml culture medium. After 24 hours, the indicated rAds were infected at various MOIs. After 48 hours, culture medium of each well was collected, the concentrations of MCP-1 were determined by ELISA as described in Materials and methods and the amounts of MCP-1 produced per well were calculated. The data are means of three independent results with standard error bars. ) cells were seeded in a well of six-well plates with 5.0 ml culture medium. After 24 hours, the indicated rAds were infected at various MOIs. After 72 hours, culture medium and cells of each well were collected, the activity of HSV-tk was determined as described in Materials and methods and the amounts of HSV-tk production per well were calculated. The data are the means of three independent results with standard error bars.
Immune-gene therapy with HSV-TK and MCP-1 T Tsuchiyama et al comparable, marked killing activity, with more than 70% killing occurring at an MOI of 0.1, and 100% killing occurring at an MOI of 10, although the tumoricidal activity of Ad-tk-MCP1 was slightly diminished at MOIs lower than 0.1. However, the Ad-MCP1-tk displayed no killing activity at MOIs lower than 3.3 and displayed 60% killing even at an MOI of 33.3. Adenovirus infection caused nonspecific cell cytotoxicity at an MOI of 100 under these experimental conditions, since all cells failed to survive after being infected by Ad-lacZ at an MOI of 100. Collectively, all rAds except for Ad-MCP1-tk showed similar HSV-tk production and tumoricidal activity when similar MOIs were used for infection.
Antitumor effects of recombinant adenoviruses in vivo
The in vivo antitumor effects of Ad-tk-MNCP1 were analyzed using athymic nude mice. Despite the reduced production of MCP-1 in vitro, the growth of subcutaneous tumors was markedly suppressed when they were treated with Ad-tk-MCP1 (n ¼ 12, tumor volume 32 days after injection, 45 (Fig 5) . Unexpectedly, the administration of Ad-tk-MCP1 was significantly more effective than the combined administration of Ad-MCP1 plus Ad-tk (n ¼ 10, 220.5786.2 mm 3 , Po.05). These data suggest that the antitumor killing may be greatly enhanced when MCP-1 is introduced into a cancer cell together with HSV-tk.
MCP-1 is known to recruit and activate macrophage in vivo. Therefore, in order to more closely examine the role of MCP1 in our model system, tumor development of tumor was monitored following the administration of carrageenan, a compound known to inactivate macrophage in vivo. The antitumor effects of Ad-tk-MCP1 (n ¼ 8, tumor volume 32 days after injection, 47.5721.7 mm 3 ) were abolished when carrageenan was administered on days 3-5, and on days 12, 19 and 26 (n ¼ 8, 255.67111.4 mm 3 , Po.05) (Fig 6) . These results suggest that MCP-1 might mediate its antitumor effects through the activation of macrophages. 
Recruitment and activation of macrophages in tumor
The recruitment of macrophages by rAds infection followed by GCV treatment was analyzed immunohistochemically using an antimacrophage-specfic mAb. Most of the infiltrating mononuclear cells in animals treated with Ad-tk-MCP1 or Ad-MCP1 plus Ad-tk stained positively for the macrophage marker Mac-1 (Fig 7a, b) , but not with control IgG (Fig 7f, g ). The number of accumulated Mac-1-postive cells was much greater in the tumors treated with Ad-tk-MCP1 or Ad-MCP1 plus Adtk than in those treated with Ad-MCP1 or Ad-tk (Fig 7a-d) . In contrast, the Mac-1-positive cells were not detectable when tumors were treated with Ad-lacZ (Fig  7e) . Furthermore, histopathological analysis showed that the number of necrotic tumor cells was increased to a greater extent in tumors treated with Ad-tk-MCP1 (Fig 7k) .
The activation state of macrophages recruited into tumor tissues following infection with rAds was analyzed by measuring of TNF-a expression, a known macrophage secretagogue. 29 The levels of TNF-a mRNA were semiquantitatively measured in the tumors using RT-PCR. TNF-a mRNA became detectable in the tumor treated with Ad-tk-MCP1 (Fig 8a, lane 1) after 25 cycles of PCR, and was clearly found in the tumors treated with Ad-tk-MCP1 and Ad-MCP1 plus Ad-tk (Fig 8b, lanes  1,2) , respectively after 30 cycles of PCR. In addition, TNF-a mRNA can hardly be detected in the tumors treated with Ad-tk-MCP1 and carrageenan (Fig 8b, lane  6 ) after 30 cycles of PCR. Collectively, these data demonstrate that Ad-tk-MCP1 followed by GCV treatment resulted in the recruitment and activation of macrophages in the tumor, and that these cells might play an important role in including tumoricidal activity in vivo.
Discussion
We have recently proposed a strategy for improving the efficacy of suicide gene-based gene therapy for HCC by the combined heterochronic administration of HSV-tk and MCP-1 genes. 13 In the current study, we demonstrated that a bicistronic recombinant adenovirus vector Ad-tk-MCP1 expressing both HSV-tk and MCP-1 in sequence under the transcriptional control of a single promoter exerted the enhanced antitumor effects in a model of HCC. Moreover, the antitumor effects of the bicistronic vector were dependent on the recruitment and activation of macrophages, since these effects were markedly reduced by the administration of carrageenan, a compound known to inactivate macrophages. 28 In contrast, another bicistronic vector Ad-MCP1-tk that expresses MCP-1 and HSV-tk in sequence demonstrated a markedly reduced level of antitumor effectiveness.
Bicistronic vectors using IRES sequences are widely used to coexpress heterologous genes in a single vector, so that promoter interference, which occurs when using heterologous promoters, does not occur. [18] [19] [20] 30 Previous studies demonstrated that the level of IRES-dependent gene expression varied from 6 to 100% of that of the promoter-dependent gene in vitro (HeLa, and CHO cells) and in vivo (mouse liver), suggesting that the gene needed for higher expression may be positioned as the promoterdependent gene. 31 In some studies on cancer gene therapy, the cytokine and suicide genes were positioned as the promote-dependent and IRES-dependent genes, respectively, [32] [33] [34] and in other studies, they were positioned in opposite sequence. 35 Although results from these studies showed that tumor regression was enhanced when suicide and cytokine gene therapies were combined, no comparison were made between the vectors harboring the two genes in different sequences.
Our data showed that the relative capacities of IRES to mediate the expression of the downstream gene were about 6-12% in the case of MCP-1 and 1-4% in the case of HSV-tk, respectively, when compared with products translated in a promoter-dependent manner in the two bicistronic rAds, Ad-tk-MCP1 and Ad-MCP1-tk, in vitro. These results were consistent with a previous report that Figure 6 Suppression of antitumor effects by carrageenan administration in vivo. Athymic mice were subcutaneously injected with 1 Â 10 7 HuH7 cells on day 0. On days 3 and 4, 1 Â 10 7 TCID 50 of rAd Ad-tk-MCP1, Ad-tk or Ad-lacZ was injected into the tumor foci. Subsequently, 75 mg/kg of GCV was administered for five consecutive days (days 5-9). In Ad-tk-MCP1 group, 1 ml of 2 mg/ml carrageenan was administered into the peritoneal cavity of the mice (Ad-tk-MCP1 carr.) on days 3, 4, 5, 12, 19 and 26. Tumor sizes were measured every 3 days. The data are representative of two independent experiments. * Po.05 when compared to Ad-tk-MCP1 by Mann-Whitney U-test.
Immune-gene therapy with HSV-TK and MCP-1 T Tsuchiyama et al showed that IRES-dependent gene expression was less efficient than the promoter-dependent expression and that their efficiencies varied depending on the nature of the cell type and reporter genes. 31 Moreover, our data suggest that the level of MCP-1 production under the control of CAG promoter may be diminished by the simultaneous expression of HSV-tk, while the HSV-tk production did not change markedly regardless of whether the MCP-1 gene was absent or present. It is possible that MCP-1 expression was inhibited by the coexistence of intracellular HSV-tk, which may have influenced the transcription efficiency of the transformed cells. [36] [37] [38] In addition, our results demonstrated that the administration of Adtk-MCP1 was significantly more effective than that of Ad-MCP1-tk and that of Ad-tk was more effective than that of Ad-MCP1 in vivo. We propose that the HSV-tk/GCV system should be mainly delivered and MCP-1 should be supported when the gene therapy was carried out using MCP-1 gene and HSV-tk gene.
The antitumor effects of Ad-tk-MCP1 were dependent on the activation of macrophages. This conclusion is supported by our data showing recruitment of macrophages into the subcutaneous tumors injected with the vector, by an increase in TNF-a production by the macrophages in the tumor, and by the fact that this antitumor effect was abolished by the administration of carrageenan. We previously demonstrated that TNF-a production was significantly augmented when macrophages were exposed to apoptotic HuH7 cells induced by HSV-tk/GCV in vitro. 13 Under the current experimental conditions, infection with Ad-tk-MCP1 was more effective in terms of tumor suppression than was codelivery of Bands corresponding to TNF-a (585 bp) and GAPDH (265 bp) were detected. M, marker (X174 hae III); 1, Ad-tk-MCP1; 2, ADMCP1+Ad-tk; 3, Ad-tk; 4, Ad-MCP1; 5, Ad-lacZ; 6, Ad-tk-MCP1 carrageenan; P, positive marker (splenocyte treated with 1 mg/ml of lipopolysaccharide); N, negative control (sterilized water).
Immune-gene therapy with HSV-TK and MCP-1 T Tsuchiyama et al Ad-MCP1, although MCP-1 production was much less with Ad-tk-MCP1 than Codelivery of Ad-tk and Ad-MCP1. Ad-tk-MCP1 infection may have resulted in efficient expression of MCP-1 in HuH7 cells, which may have become apoptotic because of the efficient expression of HSV-tk in the presence of GCV. Thus, MCP-1 secreted by apoptotic HuH7 cells may have recruited macrophages more efficiently to these apoptotic cells, thereby resulting in more deleterious effects on tumor formation. MCP-1 was reported to be destructive in some tumor models [39] [40] [41] but protective in others 42, 43 . Thus, murine colon carcinoma cell expressing MCP-1 failed to metastasize when injected into mice, 39 whereas other carcinoma cells showed enhanced metastasis. 42 A recent report demonstrated that monocyte recruitment depended on the level of MCP-1 secreted by the tumor cells and that the effect of monocytes infiltration on tumor growth was dependent on their levels of infiltration. Lower MCP-1 productions had little effect on monocyte infiltration, where as higher production levels appeared to lead to massive infiltration of monocytes/macrophages and eventually tumor destruction. 44 Our results demonstrated that the growth of subcutaneous tumors was not suppressed and massive infiltration of macrophages did not occur when tumor cells were treated with Ad-MCP1 alone. However, despite the relatively reduced MCP-1 production in vitro, the growth of subcutaneous tumors was markedly suppressed and a strong infiltration of macrophages was observed when cells were treated with Ad-tk-MCP1. Several investigators reported that dying HSV-tkmodified cells released soluble factors including cytokines. These factors, in turn, could affect the tumor microenvironment, leading to necrosis and inflammations, infiltration of immune cells, upregulation of costimulatory molecules and the generation of an antitumorigenic immune response. 45, 46 In this immunotherapeutically favorable setting, even a minute amount of MCP-1 may stimulate tumor-specific immune-mediated cell killing and enhance local antitumorigenic efficacy, thereby adding to the overall therapeutic effect.
In our experimental system, antitumor effects were evaluated in athymic nude mice that lack T-lymphocytemediated immune responses but which have preserved macrophage numbers and function. 47 Hence, it is possible that the antitumor effects reported above could be enhanced in immunocompetent mice as a result of the recruitment and activation of macrophages in tumor tissues induced by T-lymphocyte-mediated immune responses, such as the secretion of proinflammatory cytokines, such as TNF-a . Therefore, it would be interesting to see the effects in immune-competent animal models in future.
Although the data presented here are promising, a number of problems remain to be solved before this approach could be used clinically. First, subcutaneous tumor models using an HCC cell line may not be fully comparable to HCCs in patients. In consideration of the practical use, it is important to examine the treatment for large tumors. Although we tried to treat large tumors, the antitumor effect was neither sufficient nor reproducible. This could be because of the following reasons: (a) Owing to the adenovirus-specific spatial and temporal expression pattern characterized by production of high amounts of the transgene for a limited time, the desired optimal biological response may not have been elicited in large tumors. 48 (b) The viable tumor cells may remain because of insufficient gene transduction using our vectors. 48, 49 Thus, better gene delivery methods need to be developed to treat large tumors. However, in cases of nonsurgical procedures for HCC treatment in patients, such as percutaneous ethanol injection therapy, percutaneous microwave coagulation therapy 50 and radiofrequency ablation, 51 administration of the described recombinant Ad vectors could be easily applicable immediately after these standard nonsurgical procedures are complete the help promote tumor cell killing. The systemic administration of the high doses of rAds could also cause severe unexpected side effects. 52 Therefore, the use of Ad-tk-MCP1 is thought to be preferable to Ad-MCP1 plus Ad-tk, in spite of the fact that the tumoricidal activity of Ad-tk-MCP1 was comparable to that of a double dose of Ad-MCP1 plus Ad-tk (data not shown). Although the problems of rAd vectors needs to be resolved before they can be used clinically, the current study suggests a new approach that incorporates the use of immune-gene therapy with the use of a suicide gene system for the treatment of HCC and tumors of other lineages.
